Transplantation study of iPS cell-derived cardiomyocytes in non-human primates

2020 Fiscal Year Final Research Report

• Project/Area Number: 17H04173
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Shinshu University
• Principal Investigator: Shiba Yuji 信州大学, 学術研究院医学系, 教授 (70613503)
• Project Period (FY): 2017-04-01 – 2021-03-31
• Keywords: 再生医療 / 多能性幹細胞 / 心不全

Outline of Final Research Achievements

We performed three experiments itemized below to facilitate cardiac regeneration with iPS cell-derived cardiomyocytes (iPSC-CMs).
1) Autologous transplantation study of iPSC-CMs in chronic infarct model of non-human primates: We have generated iPS cell lines from six animals and generated cardiomyocytes. 2) Establishment of immunosuppression protocol following iPSC-CMs: We generated monkey iPS cell lines expressing AKaluc for bioluminescent imaging. 3) Transplantation study of iPSC-derived ventricular cardiomyocytes to control post-transplantation arrhythmia: We transplanted iPSC-ventricular CMs into 5 monkeys and found that the recipients tended to show less incidence of ventricular arrhythmia compared to those transplatned with iPSC-CMs

Free Research Field

循環器内科

Academic Significance and Societal Importance of the Research Achievements

心不全は患者数、死亡率ともに高く、心臓移植以外の根本的治療の開発が必要である。多能性幹細胞（ES細胞またはiPS細胞）を用いた心筋再生治療が期待され、複数の研究機関で臨床試験が開始されている。しかし、この治療が標準的な治療として定着するためには多くの課題が残されている。本研究成果により、より有効で安全性の高い心筋再生治療の開発が期待される。